Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > Midatech's Glioblastoma Drug and xB3 Synergy:
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2261)
•••
Comment by Boomskidon Jan 15, 2023 6:51pm
77 Views
Post# 35224543

RE:RE:RE:RE:RE:RE:RE:RE:Midatech's Glioblastoma Drug and xB3 Synergy:

RE:RE:RE:RE:RE:RE:RE:RE:Midatech's Glioblastoma Drug and xB3 Synergy:It appears to me that Midatech would have to punch a lot of little holes in a patient's cranium to approach the distribution capabilities of xB3.

Midatech's technology seems to be more like unltrasonic/microbubble delivery to precise locations rather than having a broader distribution. And I think, that like ultrasound, Midatech could deliver some otherwise very toxic drugs to a very precise location such as a solid tumour and that would be its essential medical service.

xB3 can deliver drugs throughout the CNS without surgery, intracranial injections or other physical disruptions of the BBB, blood vessels, the cranium, etc.

And xB3 can deliver drugs to diffuse tumours, litlle itty-bitty tumours as small as single digit cell counts. Midatech can't do that. A drug placed in a specific location in the CNS is generally not distributed away from that spot to any great therapeutic benefit. That's one reason why intrathecal injections of drugs are not effective beyond the immediate injection point.

And that is precisely the problem that xB3 solves and it's why xB3 is worth so effing much money!!

Which is why LT and The Placee want xB3.

Sorry, I get wound up about xB3.

jd
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities